Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 2
2001 1
2004 1
2007 1
2008 1
2009 2
2010 2
2011 5
2012 5
2013 1
2014 2
2015 2
2016 2
2017 1
2018 3
2019 3
2020 2
2021 3
2022 2
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis.
Kanu JE, Soldera J. Kanu JE, et al. World J Gastroenterol. 2024 Mar 7;30(9):1213-1223. doi: 10.3748/wjg.v30.i9.1213. World J Gastroenterol. 2024. PMID: 38577188 Free PMC article.
METHODS: This study, following PRISMA 2020 guidelines, conducted a systematic review and meta-analysis by searching MEDLINE and Scopus libraries for randomized clinical trials (RCTs) or observational studies with the following command: [("Helicobacter pylori" OR "H pylori") AND ( …
METHODS: This study, following PRISMA 2020 guidelines, conducted a systematic review and meta-analysis by searching MEDLINE and Scopus libra …
Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling.
Wu K, Li X, Zhou Z, Zhao Y, Su M, Cheng Z, Wu X, Huang Z, Jin X, Li J, Zhang M, Liu J, Liu B. Wu K, et al. Front Pharmacol. 2024 Feb 16;15:1330855. doi: 10.3389/fphar.2024.1330855. eCollection 2024. Front Pharmacol. 2024. PMID: 38434709 Free PMC article.
Case studies are presented to assess and compare five potassium-competitive acid blocker (P-CAB) compounds, after calibration and verification using vonoprazan and revaprazan....
Case studies are presented to assess and compare five potassium-competitive acid blocker (P-CAB) compounds, after calibration and verificati …
Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect.
Zou S, Ouyang M, Cheng Q, Shi X, Sun M. Zou S, et al. Pharmacotherapy. 2024 Feb;44(2):171-183. doi: 10.1002/phar.2899. Epub 2023 Dec 12. Pharmacotherapy. 2024. PMID: 38049205
In terms of nocturnal acid-inhibitory effects, the overall results showed that tegoprazan (SUCRA 91.8%) and vonoprazan (SUCRA 91.0%) had the best performance, followed by new PPIs (including tenatoprazole and ilaprazole) (SUCRA 76.6%), additional H2RAs once at bedtime (AHB) (SUCR …
In terms of nocturnal acid-inhibitory effects, the overall results showed that tegoprazan (SUCRA 91.8%) and vonoprazan (SUCRA 91.0%) had the …
Sodium alginate-based smart gastro-retentive drug delivery system of revaprazan loaded SLNs; Formulation and characterization.
Raja HN, Din FU, Shabbir K, Khan S, Alamri AH, Al Awadh AA, Lahiq AA, Alasiri A. Raja HN, et al. Int J Biol Macromol. 2023 Dec 31;253(Pt 6):127402. doi: 10.1016/j.ijbiomac.2023.127402. Epub 2023 Oct 11. Int J Biol Macromol. 2023. PMID: 37832620
Revaprazan (REV), a novel reversible Proton Pump Inhibitor (PPI) used to treat peptic ulcers, faces challenges in therapeutic efficacy due to its poor dissolution properties and a short half-life. ...
Revaprazan (REV), a novel reversible Proton Pump Inhibitor (PPI) used to treat peptic ulcers, faces challenges in therapeutic efficac …
A cochleate formulation optimized by D-optimal mixture design enhances oral bioavailability of Revaprazan.
Goo YT, Kim MS, Choi JY, Sin GH, Hong SH, Kim CH, Choi YW. Goo YT, et al. J Liposome Res. 2024 Mar;34(1):31-43. doi: 10.1080/08982104.2023.2209171. Epub 2023 May 9. J Liposome Res. 2024. PMID: 37158827
A cochleate formulation was developed to enhance the oral bioavailability of revaprazan (RVP). Dimyristoyl phosphatidylcholine (DMPC) liposome containing dicetyl phosphate (DCP) successfully formed a cochleate after treatment with CaCl(2), whereas that containing sodium de …
A cochleate formulation was developed to enhance the oral bioavailability of revaprazan (RVP). Dimyristoyl phosphatidylcholine (DMPC) …
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
Tanaka S, Morita M, Yamagishi T, Madapally HV, Hayashida K, Khandelia H, Gerle C, Shigematsu H, Oshima A, Abe K. Tanaka S, et al. J Med Chem. 2022 Jun 9;65(11):7843-7853. doi: 10.1021/acs.jmedchem.2c00338. Epub 2022 May 23. J Med Chem. 2022. PMID: 35604136
We show crystal and cryo-EM structures of the gastric proton pump in complex with four different P-CABs, tegoprazan, soraprazan, PF-03716556 and revaprazan, at resolutions reaching 2.8 A. The structures describe molecular details of their interactions and are supported by …
We show crystal and cryo-EM structures of the gastric proton pump in complex with four different P-CABs, tegoprazan, soraprazan, PF-03716556 …
Enhanced dissolution and bioavailability of revaprazan using self-nanoemulsifying drug delivery system.
Goo YT, Sa CK, Kim MS, Sin GH, Kim CH, Kim HK, Kang MJ, Lee S, Choi YW. Goo YT, et al. Pharm Dev Technol. 2022 Apr;27(4):414-424. doi: 10.1080/10837450.2022.2070644. Epub 2022 May 5. Pharm Dev Technol. 2022. PMID: 35467467
A self-nanoemulsifying drug delivery system (SNEDDS) was developed to enhance the dissolution and oral bioavailability (BA) of revaprazan (RVP). Various SNEDDSs containing 200 mg of RVP were formulated using Capmul MCM, Tween 80, and Brij L4, and they were characterized ac …
A self-nanoemulsifying drug delivery system (SNEDDS) was developed to enhance the dissolution and oral bioavailability (BA) of revaprazan …
Development of a Solid Supersaturable Micelle of Revaprazan for Improved Dissolution and Oral Bioavailability Using Box-Behnken Design.
Goo YT, Sa CK, Choi JY, Kim MS, Kim CH, Kim HK, Choi YW. Goo YT, et al. Int J Nanomedicine. 2021 Feb 17;16:1245-1259. doi: 10.2147/IJN.S298450. eCollection 2021. Int J Nanomedicine. 2021. PMID: 33633449 Free PMC article.
PURPOSE: To enhance the oral bioavailability of revaprazan (RVP), a novel solid, supersaturable micelle (SSuM) was developed. ...
PURPOSE: To enhance the oral bioavailability of revaprazan (RVP), a novel solid, supersaturable micelle (SSuM) was developed. ...
43 results